Celltrion submits MAA to EMA for regdanvimab

Oct 5, 2021

Celltrion announced that it has submitted a Marketing Authorisation Application to the EMA seeking approval of regdanvimab for the treatment of COVID-19 in adults who do not require supplemental oxygen therapy and who are at increased risk of progressing to severe COVID-19.

Print Page Mail Article